A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.

Recruiting

Phase 3

Sponsor:

AstraZeneca

Code:

NCT06268873

Conditions

Chronic Kidney Disease and Hypertension

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Baxdrostat/dapagliflozin

Dapagliflozin in combination with placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information